Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 36 % of short-term debt in 2025; threshold 65 %.
-
Busy address KBO
16 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
PHARMACIES BIOT-GYSELINCK from Faimes, company number BE0864202692, closed financial year 2025 with a result of € 205,319 after tax. For that financial year PHARMACIES BIOT-GYSELINCK recorded a gross margin of € 523,761 and equity of € 854,811. Compared with financial year 2024, the result moved from € 149,974 to € 205,319. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.
€ 854,811
▲ 14% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 205,319
▲ 37% vs 2024
Profit after tax over the fiscal year.
€ 84,887
▼ 80% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 100,000 paid out
49 % of the profit went to the shareholders, mostly to PHARMACIE LEJEUNE (100 % of the shares). That is where the money ends up.
People and assets in 2025
3.1
▲ 0.2 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 179,668
▲ 4% vs 2024
€ 58,000 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 16,290
▲ 117% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 67,214
▼ 23% vs 2024
€ 20,448 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 133,287
▼ 10% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 35,405
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 322,113 | € 378,912 | € 405,471 | € 523,761 | ▲ 29% |
| Profit after taxes | € 86,962 | € 138,894 | € 149,974 | € 205,319 | ▲ 37% |
| Equity | € 460,624 | € 599,519 | € 749,492 | € 854,811 | ▲ 14% |
| Total debts | € 213,614 | € 192,859 | € 595,744 | € 659,412 | ▲ 11% |
| Cash | € 185,484 | € 269,227 | € 415,423 | € 84,887 | ▼ 80% |
| Land & buildings | € 283,984 | € 267,713 | € 251,442 | € 581,784 | ▲ 131% |
| Retained profit | € 410,624 | € 549,519 | € 699,492 | € 804,811 | ▲ 15% |
| Dividend | € 0 | € 0 | € 0 | € 100,000 | |
| Bank debt | € 127,341 | € 107,500 | € 87,458 | € 67,214 | ▼ 23% |
| Balance sheet total | € 674,239 | € 792,378 | € 1,345,236 | € 1,514,223 | ▲ 13% |
| Employees (FTE) | 3.9 | 2.9 | 2.9 | 3.1 | ▲ 0.2 |
Key figures of PHARMACIES BIOT-GYSELINCK, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMACIES BIOT-GYSELINCK?
What happened at PHARMACIES BIOT-GYSELINCK in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 205,319 (▲ 37% vs 2024). Source: NBB ↗
- New establishment in Marchin. KBO
- Start of the company according to the CBE. KBO
- New establishment in Marchin. KBO
In short
From € 86,962 profit in 2022 to € 205,319 profit in 2025.
Paid € 203,381 in corporate taxes since 2022.
Best year ever: 2025, with € 205,319 profit.
On average € 169,000 of value added per employee in 2025.
A new publication or filing at PHARMACIES BIOT-GYSELINCK? We notify you, reason included.
Follow PHARMACIES BIOT-GYSELINCKDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of PHARMACIE LEJEUNE comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
PHARMACIES BIOT-GYSELINCKBehind PHARMACIES BIOT-GYSELINCK is PHARMACIE LEJEUNE SA. The shares are held by PHARMACIE LEJEUNE (100%).
Directors
According to the 2025 annual accounts
Director · represented by François-Xavier OLIVIER
Also active at: PHARMACIE BEAUMONT, Pharmacie J.P. Detry - Discry, PHARMACIE DES FORGES, PHARMACIE DE DONCEEL, PHARMACIE DUBOIS-HUSSON, Pharmacie DETRY-DUPONT, PHARMACIE R. WALNIER, Pharmacie BILLEN +10 more
Shareholders
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Rue de la Champignotte(AIN) 13
4317 Faimes
Place de Belle-Maison 20
4570 Marchin
Active since 11 March 2004
Rue Joseph Wauters 12 box bis
4570 Marchin
Active since 1 September 2024
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 16 companies are registered at this address.
All companies at this address →Pharmacie J.P. Detry - Discry same network
€ 255,389 gross margin · 2025
PHARMACIE DE DONCEEL same network
€ 175,420 gross margin · 2025
PHARMACIE DUBOIS-HUSSON same network
€ 475,076 gross margin · 2025
Pharmacie DETRY-DUPONT same network
€ 297,327 gross margin · 2025
PHARMACIE R. WALNIER same network
€ 463,240 gross margin · 2025
+11 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0864.202.692
- VAT number
- BE 0864.202.692
- Registered office
- Rue de la Champignotte(AIN) 13, 4317 Faimes
- Names & denominations
- PHARMACIES BIOT-GYSELINCK
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 March 2004
- Peppol
- Active · Active since 10 Sept 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers